{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:01:51Z","timestamp":1790107311881,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":277,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023876","name":"Department of Neurology, College of Medicine, Medical University of South Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.seizure.2025.01.022","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T01:38:24Z","timestamp":1737855504000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic"],"prefix":"10.1016","volume":"126","author":[{"given":"Alexander B.","family":"Kowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-6715","authenticated-orcid":false,"given":"Sophie","family":"Schlabitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6952-430X","authenticated-orcid":false,"given":"David","family":"Steinbart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6003-936X","authenticated-orcid":false,"given":"Verena","family":"Gaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2025.01.022_bib0001","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"collaborators, S.I. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.01.022_bib0002","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1528-1157.1997.tb01128.x","article-title":"Quality of life of people with epilepsy: a European study","volume":"38","author":"Baker","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","volume":"62","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.01.022_bib0004","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2025.01.022_bib0005","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.01.022_bib0006","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.seizure.2012.06.013","article-title":"Self reported adverse effects of mono and polytherapy for epilepsy","volume":"21","author":"Andrew","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.01.022_bib0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.yebeh.2011.08.005","article-title":"Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool Adverse Events Profile","volume":"22","author":"Martins","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.01.022_bib0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","article-title":"Specific adverse effects of antiepileptic drugs\u2013A true-to-life monotherapy study","volume":"54","author":"Kowski","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.01.022_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8490639","article-title":"Adverse events of antiepileptic drugs using indonesian version of liverpool adverse events profile","volume":"2018","author":"Budikayanti","year":"2018","journal-title":"Neurol Res Int"},{"key":"10.1016\/j.seizure.2025.01.022_bib0011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e318207b073","article-title":"Adverse antiepileptic drug effects in new-onset seizures: a case-control study","volume":"76","author":"Perucca","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.01.022_bib0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0404.2011.01488.x","article-title":"Self-reported symptoms in patients on antiepileptic drugs in monotherapy","volume":"124","author":"Wieshmann","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2025.01.022_bib0013","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0014","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1528-1157.1994.tb02479.x","article-title":"Development of a novel scale to assess life fulfillment as part of the further refinement of a quality-of-life model for epilepsy","volume":"35","author":"Baker","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0016","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0017","article-title":"WHOCC - ATC\/DDD Index. ATCDDD Index 2023","author":"Health","year":"2023","journal-title":"WHO Collaborat Centre Drug Statist Methodol"},{"key":"10.1016\/j.seizure.2025.01.022_bib0018","article-title":"Multivariate Analysemethoden: Eine anwendungsorientierte Einf\u00fchrung, 14th, revised and updated edition ed","author":"Backhaus","year":"2016","journal-title":"Springer Gabler"},{"key":"10.1016\/j.seizure.2025.01.022_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2023.10.016","article-title":"Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study","volume":"113","author":"Zelano","year":"2023","journal-title":"Seizure"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2025.01.022_bib0020","first-page":"S44","article-title":"Adverse effects of valproate","volume":"25","author":"Schmidt","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.01.022_bib0021","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/bmj.1.6077.1635","article-title":"Unnecessary polypharmacy for epilepsy","volume":"1","author":"Shorvon","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.seizure.2025.01.022_bib0022","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.01.022_bib0023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.01.022_bib0024","article-title":"Erster epileptischer Anfall und Epilepsien im Erwachsenenalter, S2k-Leitlinie, 2023; Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"Holtkamp","year":"2023","journal-title":"Deutsche Gesellschaft f\u00fcr Neurologie"},{"key":"10.1016\/j.seizure.2025.01.022_bib0025","article-title":"Erster epileptischer Anfall und Epilepsien im Erwachsenenalter, S1-Leitlinie, 2017; Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"Elger","year":"2017","journal-title":"Deutsche Gesellschaft f\u00fcr Neurologie"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:40:46Z","timestamp":1772469646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S1059131125000275"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.022","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events of dual anti-seizure medication: Real-life data from a tertiary epilepsy clinic","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}